Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers.
Nasa P, Singh A, Upadhyay S, Bagadia S, Polumuru S, Shrivastava PK, Sankar R, Vijayan L, Soliman MA, Ali A, Patidar S.
Nasa P, et al.
Indian J Crit Care Med. 2020 Sep;24(9):771-776. doi: 10.5005/jp-journals-10071-23566.
Indian J Crit Care Med. 2020.
PMID: 33132558
Free PMC article.
RESULTS: The need for escalation of respiratory support was significantly lower in the tocilizumab group as compared to standard treatment (p = 0.001). The mortality at day 7 and 28 was also significantly lower in the tocilizumab group (p = 0.007 and p = 0.00 …
RESULTS: The need for escalation of respiratory support was significantly lower in the tocilizumab group as compared to standard treatment ( …